New approach aims to protect Patients' brains during aggressive leukemia therapy
NCT ID NCT05519579
Summary
This study tests whether changing when spinal fluid chemotherapy is given can reduce brain-related side effects during blinatumomab treatment for acute lymphoblastic leukemia. Researchers will give the preventive chemotherapy before and during the main treatment to see if it protects patients' nervous systems while still fighting the cancer. The study involves 20 adults with relapsed or hard-to-treat leukemia who are starting their first cycle of blinatumomab therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Northside Hospital
RECRUITINGAtlanta, Georgia, 30342, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.